Daniel SontupeMarket Access
Frank BurrellScientific Storytelling
Stacey GandlerBrand Nourishment
Paul TheisenPatient Acquisition
Joey CohenMedication Adherence
Bud BilanichSuccess Coach
Matthew DurhamOmnidynamic Marketing
Amy GilesIncreasing Engagement
Suma Ramadas, PhDMedical Affairs
Brenda SnowAuthentic Patient Voice
Pat PurcellMeeting Engagement
Matt TurnerPatient Affordability
David LinetskyPoint-of-Care Marketing
Liz KaneImpactful Strategy
Kisqali is the CDK4/6 inhibitor with the largest body of first-line evidence demonstrating consistent, ...
-- Global Phase 3 URIROX-1™ Trial Ongoing; Expect to Initiate Second Phase 3 Study, ...
RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) ...
Username
Email
Password
Confirm Password
Remember Me
Username or Email